Pharmacokinetics, Disposition, and Biotransformation of the Cardiac Myosin Inhibitor Aficamten in Humans

Cytokinetics Incorporated published this content on October 01, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 01, 2024 at 04:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]